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The APP[V717I] London (APP-Ld) mouse model recapitulates important pathological and clinical hallmarks of Alzheimer’s
disease (AD) and is therefore a valuable paradigm for evaluating therapeutic candidates. Historically, both the parenchymal
and vascular amyloid deposits, and more recently, truncated and pyroglutamate-modiﬁed Abeta3(pE)–42 species, are perceived
as important hallmarks of AD-pathology. Late stage symptoms are preceded by robust deﬁcits in orientation and memory that
correlate in time with Abeta oligomerization and GSK3β-mediated phosphorylation of endogenous murine Tau, all markers that
have gained considerable interest during the last decade. Clinical parallels with AD patients and the value of the APP-Ld transgenic
mouse model for preclinical in vivo testing of candidate drugs are discussed.
1.Introduction
Notwithstanding the vast amount of resources invested into
discovery and development of new targets and treatments,
Alzheimer’s disease (AD) remains an indication with enor-
mous unmet needs. One complicating factor for successful
drug development is the unknown etiology of idiopathic
AD. AD entails noxious aggregation of β-amyloid (Abeta)
and Tau, representing fundamental processes in disease
onset and progression [1–3]. The extracellular Abeta plaques
and intracellular neuroﬁbrillary tangles (NFTs) represent
key pathological hallmarks, but are not necessarily the pri-
mary causes of neuronal toxicity. The underlying molecular
mechanisms of plaque and tangle formation, and how they
interact, remain largely elusive. It is generally accepted
that these processes involve formation of misconfomers of
the respective proteins with increased propensity to self-
polymerize in a stepwise fashion. It is clear that the process
of aggregation is toxic and triggers neuronal degeneration.
However, no consensus exists as to the exact nature, compo-
sition, or conformation of the protein assemblies that trigger
neuronaldemise.Thissituationisreﬂectedbythefactthatno
validateddrugtargetsareknownwhosemodulationprovides
a robust therapeutic response. However, given the funda-
mental involvement of Abeta in AD—which is hypothesized
as an early instigator of toxic downstream processes in AD—
pharmacologicalinterventionofAPPpathobiology(process-
ing, clearance, and aggregation) received most interest from
the pharma industry up to now.
The identiﬁcation of the pathogenic variants of hAPP
and hPS1 genes running in families with inheritable AD
has enabled the generation of transgenic animal models,
mainly rodents, for AD (for a recent review, see [4, 5]). In
recent years, the value and limitations of AD rodent models,
both in terms of providing a better understanding of disease
pathogenesis and progression and aiding the development2 International Journal of Alzheimer’s Disease
of drugs for treating disease, have been a topic of intense
and recurrent debate in the Alzheimer ﬁeld, as is illustrated
by numerous recent reviews and opinion papers [6, 7].
Although none of the current AD rodent models fully reca-
pitulate all aspects of disease, that is, displaying a progressive
development of all speciﬁc neuropathological and cognitive
aspects of AD, some mouse models reproduce or recapitulate
at least several of the most important characteristics [8].
In this paper, we review pathological read-outs and
introduce two new neuropathological markers of the “APP
London” (APP-Ld) mouse model, that is, early-onset aggre-
gation of Abeta and subsequent appearance of truncated,
pyroglutamate-modiﬁed Abeta3–42 (Abeta3(pE)–42)a m y l o i d
peptide species in the brain. Furthermore, we discuss clinical
parallels with the human Alzheimer patient and the value
of the model for preclinical in vivo testing of candidate
Alzheimer drugs.
2.ExperimentalProcedures
2.1. Transgenic Mice. Female transgenic mice in mixed
FVB/N × C57Bl/6J background expressing heterozygously
hAPP[V717I] under control of the neuron-speciﬁc murine
thy1 gene promoter have been used in this study. The
construction of the FVB/N background strain has been
described earlier [1, 9, 10]. The F1-hybrid strain was a
crossing of heterozygous APP[V717I] males in C57Bl/6J
background with wild type FVB/N females. In addition,
double transgenic mice overexpressing hAPP[V717I] and
hPS1[A246E] were generated by crossbreeding the single
hAPP[V717I] mutant with homozygous hPS1[A426E] mice
[11]. Genotyping by two independent PCR assays per
transgene at the age of three weeks and at the onset of the
experiments on DNA extracted from tail biopsies conﬁrmed
the respective genotypes.
2.2. Animal Care and Handling. A l lt r e a t m e n t sw e r e
approved by the Local Committee for Animal Use and were
performed in accordance to state and federal regulations.
During the time of study, mice had access to preﬁltered
sterile water and standard mouse chow (Ssniﬀ Ms-H, Ssniﬀ
Spezialdi¨ aten GmbH, Soest, Germany) ad libitum and were
housedunderareversedday-nightrhythminindividualven-
tilated macrolon T2 cages in accordance to local legislation
on animal welfare.
2.3. Sacriﬁce, CSF Collection, and Brain Processing. The mice
were anaesthetized with a mixture of Anesketin (Ketamin),
Rompun (Xylazin 2%), Atropin and saline (1 : 1 : 1 : 1), and
perfused transcardiacally with ice-cold saline. Cerebrospinal
ﬂuid (CSF) was collected via an incision in the neck muscles
between the skull and the ﬁrst cervical vertebrae. A puncture
into the cisterna magna was given with a 26-gauge needle
and 10–20μL of CSF was collected with a ﬁne glass pipette.
The brain was excised from the cranium, and hindbrain
and forebrain were separated at the coronal plane. The
left and right hemispheres were separated. Routinely, one
hemisphere was immersion ﬁxed overnight in phosphate-
buﬀered saline (PBS) containing 4% paraformaldehyde for
(immuno) histology, and the other hemisphere was snap-
frozen in liquid nitrogen and stored at −80
◦C until further
use in biochemical assays.
2.4. Abeta40 and Abeta42 in CSF. Human Abeta40 and
Abeta42 concentrations in CSF were measured using com-
mercial ELISA kits according to the manufacturers protocol
( H u m a nA m y l o i d4 0o r4 2H SE L I S A ,M i l l i p o r e ) .
2.5. Abeta Immunohistochemistry. Sagittal free-ﬂoating sec-
tions (40μm) were stored in PBS containing 0,01% (w/v)
sodium azide at 4◦C until staining. Sections were washed
twice in PBS and quenched with 1.5% (v/v) hydrogen
peroxide in PBS and methanol (1 : 1) for 15 minutes
to remove endogenous peroxidase activity. After washing
the sections three times in PBS containing 0,1% Triton
X100 (PBST), sections were blocked for 30 minutes in 10%
Fetal Calf Serum (FCS) in PBST and incubated overnight
with a biotinylated anti-Abeta antibody in blocking buﬀer
(proprietary anti-Abeta Nanobody against N-terminus of
Abeta, reMYND/Ablynx). After rinsing, the sections were
incubated in 0,01% trypsin in PBS for 15 minutes at room
temperature, followed by incubation with avidin-biotin
peroxidase complex (Vectastain Elite ABC, Vector Labora-
tories). The signal was developed with 3,3
  diaminobenzi-
dine tetrahydrochloride tablets (DAB, ICN). Sections were
counterstained with Mayers hematoxylin, dehydrated and
mounted in Depex (Depex mounting medium, VWR Inter-
national). Microscopic images were recorded and digitalized
with a 3 CCD color video camera and analyzed with
dedicated software (Olympus BX41 microscope, Color view
II—Olympus camera, Analysis Five—Cell
∧D software).
2.6. Abetax–42 and Abeta3(pE)–42 Levels in Brain. Brain tis-
sue was homogenized in TBS (20mM Tris-HCl pH 7.6,
137mMNaCl) containing protease inhibitor cocktail (Com-
plete Mini, Roche), followed by sequential extractions with
1% Triton X-100 in TBS (TBS fraction), 2% SDS in water
(SDS fraction), and 70% formic acid (FA fraction). The FA
fraction was neutralized with 3.5M Tris and diluted 1 : 20
in EIA buﬀer (IBL International). Pyroglutamate-modiﬁed
Abeta (Abeta3(pE)–42) and pan-Abeta42 (Abetax–42)w e r e
assessed using speciﬁc sandwich ELISAs (IBL International).
2.7. Aggregated Abeta in Brain. A 10% (w/v) brain ho-
mogenate was prepared from each brain sample in 2%
(v/v) NP40 in PBS (NaCl 0.138M, KCl 0.0027M, pH 7.4)
containing 1mM PMSF and protease inhibitors (Complete
Mini, Roche). The 10% brain homogenates were further
diluted into buﬀer to a ﬁnal concentration that would
provide a signal within the linear range of the immunoassay.
The concentration of aggregated Abeta was measured using
a proprietary assay (Amorﬁx Aggregated Abeta Assay (A4),
Amorﬁx, Mississauga, Canada). Using a proprietary sample
enrichment protocol, only the aggregated Abeta was isolated
from each sample. Each sample was then disaggregated toInternational Journal of Alzheimer’s Disease 3
allow detection of monomeric Abeta using the Amorﬁx
Abeta immunoassay based on an europium-ﬂuorescent
bead coupled to the 4G10 antibody (N-terminal) and
magnetic beads coupled to the antibodies 1F8 and 2H12
(C-terminal) recognizing Abeta40 and Abeta42, respectively.
The europium ﬂuorescence intensity was measured using
Time Resolved Fluorescence (TRF) on each sample in
triplicate and is directly proportional to the concentration
of Abeta within the sample. The current limit of detection is
50fg/well. The S/N cutoﬀ value for all experiments was 2.0,
equaling two times the background signal from buﬀer alone.
3. Results andDiscussion
3.1. The APP-Ld Transgenic Mouse Recapitulates Early and
Late Hallmarks of Alzheimer’s Disease. The APP[V717I]
mutation is the most frequentin familial ADwith 74 families
known, versus only three with the APP Swedish muta-
tion (AD&FTD Mutation Database—http://www.molgen
.ua.ac.be/ADMutations). In the APP[V717I] mice, the Lon-
donmutantalleleisheterogeneouslyexpressedundercontrol
of the neuron-speciﬁc murine thy1 gene promoter, steering
postnatal expression to a level 2 times higher than endoge-
nous APP [9].
3.2. Late Stage Amyloid Plaque Pathology, the Object of
Historical Focus
3.2.1. Increased Abeta Levels. In the APP-Ld mouse, an
age-dependent progressive increase of both soluble and
insoluble Abeta40 and Abeta42 levels was observed in brain
extracts. Soluble Abeta42/40 ratios increased up to 1 with
age, whereas insoluble Abeta42/40 ratios were 5–10 times
higher ([11] and unpublished data). Thus, APP-Ld mice
display a high relative concentration of Abeta42, the more
ﬁbrillogenic Abeta species, essential for amyloid deposition
in the parenchyma and vessels [12]. The V717I substitution
is located downstream of the gamma-secretase cleavage site
and aﬀects the processing of the APP protein causing a shift
from Abeta40 to Abeta42 cleavage and thereby increasing
the Abeta42/40 ratio. Since processing at the α-, β-, or γ-
c l e a v a g es i t e si sn o tc l e a r l ya ﬀected by age, the production
of Abeta per se is not thought to be the primary cause of the
accumulation in the APP-Ld mouse brain [11]. Instead, the
failure of Abeta clearance or degradation has been proposed
as the underlying mechanism.
3.2.2. Parenchymal Amyloid Depositions. Parenchymal amy-
loid plaques arise at the age of 10–12 months in the entorhi-
nal cortex and subiculum (Figure 1(a))—brain regions hier-
archically involved in early stages of development of AD
pathology in patients [13, 14]—and subsequently spread to
the frontal cortex [9]. A proprietary anti-Abeta Nanobody
recognizes ﬁbrillar Abeta species with high speciﬁcity and
aﬃnity. Two types of Abeta depositions—resembling the
pathology in AD brain—develop in the brain parenchyma
of the APP-Ld mouse, that is, plaques bearing a diﬀuse
character immunoreactive to Abeta antibodies and senile
(Thioﬂavin S positive) plaques comprising an amyloid core
surrounded by a halo and neuritic processes [9, 15]. The
neuritic component contains hyperphosphorylated forms of
protein Tau detected as dystrophic processes by mAb AT8
immunohistochemistry [9] attributed to early neuroﬁbril-
lary changes in AD. In addition, plaque formation is accom-
panied by amyloid-associated neuroinﬂammation, that is,
astrocytosis and gliosis, also typically found in AD patients
[16], and can be readily detected with immunohistological
markers GFAP for staining astrocytes and CD11b/CD45 for
the total and activated microglia load, respectively.
3.2.3. Vascular Amyloid Depositions (Cerebral Amyloid
Angiopathy, CAA). At old age, the deposition of amyloid
in cerebral vessel walls is observed in the APP-Ld model,
with from 10 to more than 50 vessels aﬀected per coronal
brain section [17]. Similar to parenchymal plaque for-
mations, Abeta42 is the ﬁrst peptide to be deposited in
vessels, and as such entrapping massive amounts of soluble
Abeta40 peptide, the latter ultimately making up for the
vast majority of amyloid in vascular plaques [17]. Cerebral
amyloid angiopathy is frequent in AD [18] and the ratio of
Abeta42/40 is lower in vascular than in parenchymal plaques
[19]. The latter is explained by drainage of Abeta40 along
the perivascular space because of its higher solubility. The
morphological, ultrastructural, and biochemical aspects of
the human vascular amyloid depositions, as well as the local-
ization and the type of vessels aﬀected, are reproduced in the
APP-Ldmodelsuggestingasimilarunderlyingmechanismof
Abeta deposition [17]. Vascular amyloid leads to progressive
vessel wall damage and aneurism formation, predisposing
the mice to hemorrhage and eventual microbleeds observed
at very old age (25–30 months) reminiscent of vascular
amyloidosis in a subset of AD patients.
3.2.4. Abeta3(pE)–42 Accumulation in Plaques. T h ep r e s e n c eo f
C-truncated Abeta1-38 and N-truncated Abeta11–42 pep-
tides in APP-Ld brain extracts was demonstrated previously
in [20]. In addition, we show here that pyroglutamate-
modiﬁed Abeta3–42 (Abeta3(pE)–42), a dominant fraction of
Abeta peptides in senile plaques of AD brain [21], is detected
in the insoluble fraction of brain extracts of APP-Ld mice
from the age of 12 months onwards (Figure 2). Although
absolute levels are low in both extracts, an age-dependent
increase was observed. These N-terminal truncated Abeta
species are abundant in amyloid deposits in sporadic
and familial AD [22]. They resist proteolysis, accelerate
aggregation by seeding and thereby entrapping other Abeta
forms, and are claimed to be neurotoxic [23]. Reduction of
Abeta3(pE)–42 by inhibition of glutaminyl cyclase (QC), the
enzyme catalyzing the N-terminal pGlu modiﬁcation, was
therefore suggested as a new therapeutic target in AD [24].
3.2.5. Decreased CSF Abeta42/40 Ratio with Age. In parallel
with what is observed in AD patients [25–27], the ratio
of Abeta42/40 in CSF decreases in ageing APP-Ld mice
(Figure 3), correlating in time with the appearance of
abundant parenchymal and vascular plaque formation from4 International Journal of Alzheimer’s Disease
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Figure 1: Abeta aggregation prior to plaque formation in APP[V717I] (APP-Ld) and APP[V717I] × PS1[A246E] mice. (a) Representative
photocollectionofanti-AbetastainedsectionsshowingtotalplaqueloadinAPP-Ldmiceofdiﬀerentages(proprietaryanti-AbetaNanobody,
reMYND/Ablynx, Belgium). (b) Aggregated Abeta in APP-Ld mice of diﬀerent ages, both in preplaque (indicated by the dashed line) and
postplaque stages of the Alzheimer pathology (A
4-assay, Amorﬁx Life Sciences Ltd., Mississauga, Canada). The signal of nontransgenic mice
was under the S/N cutoﬀ value (data not shown). (c) As in B, for the APP[V717I] × PS1[A246E] model. The signal of nontransgenic mice
was under the S/N cutoﬀ value (data not shown).
the age of 15 months onwards. The ratio Abeta42/40 in CSF
could be a more valuable diagnostic tool for early-stage AD
and mild cognitive impairment (MCI) patients [25].
3.3. Early Stage Preplaque Pathology, the Object of
More Recent Focus
3.3.1. Cognitive and Behavioral Impairment. From the age
of three months onwards, robust and signiﬁcant spatial and
nonspatial orientation and memory deﬁcits are observed
in the APP-Ld model, which does not relate to the timing
of plaque deposition [9]. Accordingly, impaired NMDA-
dependent long-term potentiation and decreased NMDA-
receptor activation in hippocampal CA1 region have been
demonstrated at a preplaque age stadium. Inhibiting APP
processing rescued this eﬀect suggesting the dysfunction
of the glutamate neurotransmitter system represents a
pathologically relevant process secondary to Abeta toxicity
involving synaptic plasticity and memory formation [9, 28,
29]. Also derangement of associative learning, hyperactivity,
anxiety, and aggression develops independently of plaque
formation [30]. Some of these have been shown to be
alleviated by serotonergic drugs [31]. Premature death
caused by epileptic seizures is an epiphenomenon observed
in Alzheimer patients [32, 33] and is also found in the APP-
Ld model [9].
The preplaque synaptic and cognitive demise and related
behavioral deﬁcits in the APP-Ld mouse dissociate the late
ﬁbrillar amyloid plaques from pathobiological processes at
early age apparently elicited by speciﬁc soluble Abeta forms
inducing neuronal toxicity (see also “Abeta aggregation prior
to plaque formation”).
A similar dissociation of amyloid plaque pathology
and behavioral aspects was observed in mild cognitive
impairment (MCI) patients [34]. In addition, occurrence of
soluble aggregated Abeta forms—rather than the amyloid
plaques—in AD brain correlates in time with the onset of
cognitive decline in AD patients [35].
3.3.2. Brain Inﬂammation. In AD patients, neuroinﬂamma-
tion is recognized as an early defect in the pathogenesis [36].
In the APP-Ld model, early inﬂammation is evident as foci
of activated microglia and astroglia randomly distributed
throughout hippocampus and cortex, from the age of 3
months [37] .T h e s ef o c ih a v eb e e np r o p o s e dt or e p r e s e n t
the earliest sites of amyloid deposition, likely evolving into
amyloid plaques. Moreover, these early and focal inﬂamma-
tory events have been postulated to contribute to neuronal
dysfunction at a young age and to the early cognitive impair-
ment in the APP-Ld model. Interestingly, neuronal BACE1
expression was demonstrated to be upregulated in close
proximity of activated microglia and astrocytes, strongly
pointing to an interaction between neurodegenerative and
neuroinﬂammatory events [37].
3.3.3. Abeta Aggregation Prior to Plaque Formation. Already
at the age of two months, that is, long before the onset of
amyloid deposition and plaque formation at 10–12 months,International Journal of Alzheimer’s Disease 5
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Figure 2: Abeta3(pE)–42 determination in the SDS and FA extracts of APP-Ld brain. Pan-Abeta42 (a, b) and Abeta3(pE)–42 (c,d) concentrations
in SDS (a, c) and FA (b, d), as well as the corresponding Abeta3(pE)–42 to pan-Abeta42 ratios (in %) (e, f).
soluble oligomeric Abeta is present in brain of APP-Ld mice
and their levels gradually increase with age (Figure 1(b)).
Determination of the exact nature of these aggregated Abeta
species in the brain of APP-Ld mice, and their correlation
withthesigniﬁcantcognitivedeﬁcits,isthesubjectofcurrent
investigations.
The coincidental timing with the onset of cognitive
defects is intriguing, given that in diseased brains increases
of soluble Abeta also correlate with cognitive decline and
neuropathological hallmarks of AD [35]. A causal link of
Abeta oligomers has also been suggested by a study where
clearing of plaques, but not oligomers, did not mitigate
cognitive decline [38]. The realization of Abeta oligomers
representing noxious species has spurred research to ﬁnd
ways to inhibit their formation as a strategy for therapeutic
intervention.
3.3.4.TauPhosphorylation. Inlaterstagesofthepathologyin
APP-Ld mice, plaque-associated dystrophic neurites develop
containing hyperphosphorylated murine Tau [9]. Recent6 International Journal of Alzheimer’s Disease
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Figure 3: Progression of CSF Abeta42/40 ratios in ageing APP-Ld
mice; from the age of 15 months onwards, the ratio of Abeta42/40
in CSF decreases.
data have demonstrated GSK3β-activation and mouse Tau
phosphorylation in the hippocampus of the single APP-Ld
model at a preplaque stadium ([1, 39] and unpublished
data). These ﬁndings correlate with the presence of solu-
ble Abeta aggregates and cognitive deﬁcits suggesting an
“instigator role” of Abeta in the downstream pathobiology
mediated by kinases resulting in Tau phosphorylation.
Although the exact nature of the responsible Abeta form(s)
remain(s)elusive,anunspeciﬁedsubsetofsolubleoligomeric
species is hypothesized to be involved in the neurotoxicity
cascade [38]. Relevant in this context, knockout of the
murine Tau prevented decline of learning and memory as
well as hypersensitivity to excitotoxicity in a independent
APP transgenic mouse model [40]. The combined data
support the hypothesis that endogenous Tau is required for
Abeta-mediatedneurotoxicityinmice,illustratingapathobi-
ological interplay between Abeta and Tau in transgenic APP
mice.
3.4. The APP[V717I] × PS1[A246E] Model for Faster Rank-
ing of Lead Molecules. Complementary to the late onset
APP-Ld single transgenics, an APP[V717I] × PS1[A246E]
bigenic model (APP
∗PS1) has been developed being a
more aggressive model with accelerated amyloid pathology
[11]. These mice carry additionally the human PS1[A246E]
transgene, also under control of the murine thy1 gene pro-
moter, containing a clinical mutation in the region encod-
ing the transmembrane (AD&FTD Mutation Database—
http://www.molgen.ua.ac.be/ADMutations).
Whereas in ageing APP-Ld mice both Abeta42 and
Abeta40 are increased, in the double transgenic APP[V717I]
×PS1[A246E] mice the more hydrophobic Abeta42 is
preponderantly increased. Consequently, accelerated amy-
loid plaque pathology is observed, caused by the higher
Abeta42/40 ratio (above 1), with amyloid plaque develop-
ment at the age of 5–6 months [41].
Concomitant to the increased Abeta42 production in
the APP
∗PS1 double transgenic model, soluble aggregated
forms of Abeta during the preplaque stadium were found
two-fold increased at the age of 2–4 months compared to
thesingleAPP-Ldmodel(Figure 1(c)).TheaggravatedAbeta
pathobiology in the APP
∗PS1 double transgenic mouse
recapitulates the eﬀect of the early-onset familial Alzheimer
disease (EOFAD) PS1 mutations on the metabolism of APP
[42].
Practical advantage of the double APP
∗PS1 versus the
single APP-Ld model involves the shorter time span between
onset of amyloidosis and amyloid plaque development and
thereby the relatively faster evaluation and prioritization of
lead molecules before further drug development.
3.5. Combined and Age-Dependent Development of Amy-
loid Plaques and Neuroﬁbrillary Tangles in APP[V717I] ×
TAU[P301L] Double Transgenic Mice. Tau mutations are
linked with FTD in humans, evoking a tauopathy rem-
iniscent of that in AD, including cognitive defects and
neurodegeneration leading to dementia. In total, 32 fam-
ilies have been identiﬁed carrying this point mutation in
exon 7 (AD&FTD Mutation Database—http://www.molgen
.ua.ac.be/ADMutations).
In the single TAU[P301L] transgenics, the observed
conformational change and age-dependent accumulation of
AT8 and AT100 reactive insoluble Tau have been proposed to
trigger an age-dependent tangle pathology (starting at age 8–
9 months) [10, 43]. In parallel the TAU[P301L] mice develop
motor deﬁcits like limb clasping and impaired survival, that
is, succumbing before age 12–13 months [10]. Although this
modeldoesnotcontainanyamyloid-relatedhallmarks,ithas
beenprovenverysuitablefortherapeutictestingofcandidate
drugs aimed at Tau pathology ([10] and unpublished data).
To introduce Tau pathology in the APP-Ld mouse, the
bigenic APP[V717I] × TAU[P301L] mouse line (APP
∗TAU)
was created [1, 10]. Three important characteristics of AD
are recapitulated in this model: intracellular neuroﬁbrillary
tangles (NFTs), extracellular amyloid plaques, and cognitive
impairments. The amyloid pathology in these mice is more
intense than in the single APP-Ld mouse, but similar in
its aspects and timing [1]. NFT pathology is signiﬁcantly
enhanced in the hippocampus and cortex relative to the
parental single TAU[P301L] model, developing in the same
time frame as the amyloid plaques [1].
The bigenic APP
∗TAU model will be highly valuable for
further investigating the molecular interplay between Abeta
and protein Tau in causing neurodegeneration and as a tool
to evaluate drug candidates.
4. Conclusions
During the past decades, a variety of rodent models have
been developed and proven to be valuable tools for decipher-
ing the complexity of AD and contributed to the discovery
and development of diagnostic and therapeutic innovations.
However, the current AD animal models have their limita-
tions and may, at least partly, contribute to the high failure
rates of AD drug candidates in clinical trials. Apart from
the obvious gap between mice and men, the translational
gap also stems from diﬀerences in etiological factors, spatio-
temporal onset of pathology, and brain physiology [6].International Journal of Alzheimer’s Disease 7
Notwithstanding the above, the AD mouse models are of
utmost importance for the exploration of novel therapeutic
approaches. Given the particularities and limitations of
the animal models, the single most important parameter
for meaningful proof-of-concept studies is the selection of
the most appropriate animal model which most faithfully
recapitulates the key parameters of disease. In addition,
preclinical proof-of-concept studies should ideally be per-
formed in more than one model to capture as much
disease pathology as possible and to discern animal and
model speciﬁc artifacts. For instance, by analyzing two
models with diﬀerent APP mutations, compounds acting
speciﬁc in the context of one particular mutation would be
distinguished.
The APP-Ld mouse model for amyloid pathology rep-
resents a highly valuable model for drug testing, especially
when targeting the amyloid cascade, but also for modulators
of beginning Tau pathology. As summarized in this paper,
the processing of human APP-Ld and production of Abeta
in APP-Ld mice result in a plethora of pathological and
behavioral eﬀects modeling key disease parameters of AD.
Development of amyloyd plaque pathology in brain
parenchyma and vasculature, and related inﬂammatory pro-
cesses (astrocytosis, microgliosis) arise in an age-dependent
way. Concomitant clearance of Abeta to CSF is aﬀected as
a presumed consequence of massive deposition of Abeta.
Thus,theresultantdecreaseofAbetaCSF(infunctionofage)
closely mimics the situation in AD patients and provides an
eﬃcacy biomarker in preclinical studies directed to evaluate
Abeta-modulating drugs.
The novel data on the presence of insoluble pyrogluta-
mate-modiﬁed Abeta3–42 in the brain of aged APP-Ld mice
oﬀer alternative therapeutic options. N-terminal truncated
Abeta is highly abundant in AD brain and is believed to be
an initiator of the Abeta aggregation cascade because of its
exceptional physical properties. The conservation of the QC
mediated posttranslational modiﬁcation process provides
unique opportunities to study the role of pyroglutamate-
modiﬁed Abeta in AD and for testing novel QC inhibitors
for therapeutic potential.
EarlyformedsolubleaggregatesofAbeta(asof2months)
in brain of APP-Ld mice suggest that these Abeta miscon-
formers are primary triggers of synaptic and neurotoxicity.
The similarity with AD patients is striking, especially in
light of recent ﬁndings demonstrating that soluble oligomers
species were elevated in AD brain and appear to correlate
with cognitive decline and neuropathological hallmarks
[35]. Although the exact nature of the toxic Abeta species
remains elusive, more than 25 years after their discovery, this
ﬁnding can have an important impact on drug development
strategies aimed at Abeta pathobiology.
Abeta-mediated activation of GSK3β-kinases and phos-
phorylation of endogenous mouse Tau in APP-Ld mouse
brain reﬂect an intriguing and potentially very important
connection between Abeta and Tau pathology [1]. Thus,
the APP-Ld transgenics also model disease relevant Tau
pathology [40] and would permit studies of Abeta eﬀects on
Tau pathology and assessing the therapeutic potential of Tau
modulators.
Collectively, APP-Ld mice recapitulate the AD-related
development and progression of Abeta pathobiology and its
downstream eﬀects on cognition and Tau most closely, how-
ever, without neuroﬁbrillary tangles and massive neuronal
loss. This positions the APP-Ld mouse model as a valuable
tool for detecting and analyzing Abeta and Tau modulating
AD drugs with the potential to fundamentally modify the
course of the disease. By combining APP-Ld with mutant
PS1, a further aggravated Abeta pathology is obtained
providing practical advances for especially proof-of-concept
studies of drug candidates. The APP-Ld
∗TAU-P301L double
transgenicsoﬀertheadvantageofamorecompletepathology
facilitating research and drug development focusing or
addressing the interplay of Abeta and Tau in onset and
progression of AD.
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